This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content may only be relevant to HCPs practising in Great Britain (England, Scotland and Wales) according to product availability. This website is optimised for desktop use, and some features may perform differently on mobile devices.
Adverse event reporting can be found at the bottom of the page.
(dupilumab) in uncontrolled Chronic Obstructive Pulmonary Disease
Patient Identification
Indication
DUPIXENT is indicated in adults as add-on maintenance treatment for uncontrolled COPD characterised by raised blood eosinophils on a combination of an ICS, a LABA, and a LAMA, or on a combination of a LABA and a LAMA if ICS is not appropriate.1
Please refer to the Summary of Product Characteristics for further information.1
Are eligible patients with COPD ready for MORE I CAN MOMENTS?
Your patient with uncontrolled COPD may be a candidate for DUPIXENT. Consider DUPIXENT in eligible patients with:
Triple therapy
Uncontrolled COPD on triple inhaled therapy, or double inhaled therapy if ICS is not appropriate1,2
Exacerbations
Experienced ≥2 moderate exacerbations or ≥1 severe exacerbation in the previous year1,2
EOS
Type 2 inflammation: Raised blood eosinophil levels (≥300 cells/µL)1,2
A raised blood eosinophil level is recognised by the 2025 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Report as a clinically useful biomarker in identifying COPD with type 2 inflammation2
Felix’s clinical history Age: 63
Patient profiles are fictional and have been produced for the purposes of medical education. Any actual or potential likeness to real individuals is unintentional. Individual patient responses can vary.
“It’s hard to make it through a workday. I have to sit down and rest before I can finish my mail route. And coughing up so much mucus is tough. I want to work until I’m 70 and enjoy retirement with my family, but I'm not sure my COPD will allow that.”
On optimised inhaled therapy (ICS, LAMA, LABA; 1 dose per day)
Evidence of type 2 inflammation:1,2 raised blood eosinophil levels (310 cells/μL)
Two moderate exacerbations requiring treatment with oral corticosteroids (OCS) in the past year
Quit smoking at age 43, 15 pack-year history
4 years since COPD diagnosis
Forced vital capacity (FVC): 2.7 L; forced expiratory volume in 1 second (FEV1)/FVC: 0.59; post-bronchodilator (BD) FEV1: 1.8 L (63% predicted)
Treatment goal: Improve breathing, reduce mucus, enjoy quality time with family
Treatment challenge: Felix remains symptomatic despite being on optimised inhaled therapy for 14 months.
Patient profiles are fictional and have been produced for the purposes of medical education. Any actual or potential likeness to real individuals is unintentional. Individual patient responses can vary.
“I was in the ICU earlier this year. I used to get out to run errands, but now I’m chained to oxygen at home. I can barely make it to my mailbox. I’m scared that if I go back into the hospital, I might not come home again.”
On optimised inhaled therapy (LAMA, LABA; 1 dose per day; ICS was not appropriate)
Evidence of type 2 inflammation:1,2 raised blood eosinophil levels (480 cells/μL)
One severe exacerbation requiring hospitalisation in the past year
Treatment challenge: Rita recently quit smoking after several attempts, but her exacerbations have been severe. With each exacerbation increasing the risk of more, the situation is urgent3
DUPIXENT (dupilumab). Summary of Product Characteristics. 2025. Date last accessed: January 2026.
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2025 report). Available at: https://goldcopd.org/2025-gold-report/ Date last accessed: January 2026.
Suissa S, Dell’Aniello S, Ernst P. Thorax. 2012;67(11):957‑963.
